2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III R... by Chau, I, Park, J.O, Ryoo, B.Y, Yen, C.J, Poon, R, Pastorelli, D, Blanc, J.F, Kudo, M, Pfiffer, T.F, Hatano, E, Chung, H.C, Kubackova, K, Phelip, J.M, Brandi, G, Ohkawa, S, Li, C.P, Okusaka, T, Yang, L, Abada, P, Zhu, A

Get full text

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade by Blanc, J.-F, Chan, S.L, Park, J.O, Ryoo, B.-Y, Yen, C.-J, Kudo, M, Poon, R, Pastorelli, D, Baron, A, Pfiffer, T.F, Okusaka, T, Kubackova, K, Trojan, J, Sastre, J, Chau, I, Abada, P, Chang, S.-C, Yang, L, Zhu, A

Get full text

SAT-076 - Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade by Blanc, J.-F., Chan, S.L., Park, J.O., Ryoo, B.-Y., Yen, C.-J., Kudo, M., Poon, R., Pastorelli, D., Baron, A., Pfiffer, T.F., Okusaka, T., Kubackova, K., Trojan, J., Sastre, J., Chau, I., Abada, P., Chang, S.-C., Yang, L., Zhu, A.

Get full text